ライフサイエンスコーパス: blood loss

1 esthesiologists class and surgical severity (blood loss).

2 ate in prolonged field care following severe blood loss.

3 r organ transplantations to reduce excessive blood loss.

4 isol, albumin, age, duration of surgery, and blood loss.

5 P < 0.05) and had reduced risk of excessive blood loss.

6 der patients with significant intraoperative blood loss.

7 for older patients with significant surgical blood loss.

8 t difference in the amount of intraoperative blood loss.

9 ically ill patients, due to inflammation and blood loss.

10 surgical injury and may result in increased blood loss.

11 There was no difference in blood loss.

12 surgical injury and may result in increased blood loss.

13 , culminating in a physical barrier to limit blood loss.

14 nia, and platelet consumption due to massive blood loss.

15 ncreased in relationship to the magnitude of blood loss.

16 levels between 30% and 35.9% and <500 mL of blood loss.

17 associated with surgical incision and lower blood loss.

18 old more effective than KD1-WT in preventing blood loss.

19 associated with surgical incision and lower blood loss.

20 cing surgical success and minimizing overall blood loss.

21 ted surgical teams in reducing the amount of blood loss.

22 cers, and a higher incidence of fecal occult blood loss.

23 on receive antifibrinolytic therapy to limit blood loss.

24 All the agents reduced blood loss.

25 ic plug integrity is critical for preventing blood loss.

26 s, administered the study drug, and measured blood loss.

27 botomy and pharmacologic agents for limiting blood loss.

28 ional status, and significant intraoperative blood loss.

29 ate of acute postpartum haemorrhage and mean blood loss.

30 traoperative bleeding reduces intraoperative blood loss.

31 logical stress, such as infection or chronic blood loss.

32 eal phase deficiency, long menses, and heavy blood loss.

33 terature, few focus on directly quantitating blood loss.

34 o fibrin to stabilize blood clots and reduce blood loss.

35 Primary endpoint was intraoperative blood loss.

36 preoperative diagnosis, operative time, and blood loss.

37 competence and influences the perioperative blood loss.

38 n failure and death, despite the stemming of blood loss.

39 were higher grade, stage, and intraoperative blood loss.

40 to short coat hair, disease transmission and blood loss.

41 orrhage and exhibit a delay in recovery from blood loss.

42 reased risk of transfusion despite increased blood loss.

43 low was preserved during moderate and severe blood losses.

44 roup showed longer operative time and higher blood losses.

45 Body mass index was 29 (23-43), estimated blood loss 1.0 L (0-23), and operating room time 160 min

46 iques: operative times (99 vs. 182 minutes), blood loss (102 vs. 325 ml), transfusion requirement (2

47 The incidence of high blood loss (13.3%), conversion (2.2%), and leaks (5.8%)

48 on (20 minutes versus 30 minutes, P = 0.01), blood loss (150 mL versus 250 mL, P = 0.034), and operat

49 s (402 vs 322 minutes; P < 0.001), operative blood loss (18 vs 14 packed red blood cell units; P = 0.

50 ed median procedure time (2.9 vs 3.7 hours), blood loss (200 vs 1000 mL), transfusion requirement (0

51 Lower blood loss (250 vs 400 mL, P = 0.001), less overall morb

52 ssociated with a decrease in mean postpartum blood loss (262.3 mL to 214.3 mL, p<0.0001).

53 mpared with ovulatory cycles (geometric mean blood loss: 29.6 vs. 47.2 mL; P = 0.07).

54 d the survival of rats subjected to profound blood loss (33.5 mL/kg) despite administration of only a

55 P < 0.01) and showed an increased amount of blood loss (350 [20-1500] mL vs 100 [10-1100] mL, P = 0.

56 LLP patients had lower average blood loss (357 vs. 588 mL, P < 0.01), fewer complicatio

57 operative time (263 minutes), intraoperative blood loss (425 mL), median length of stay (9.5 days), o

58 (50.8 vs 77.3 minutes), lower intraoperative blood loss (52.7 vs 97.8 mL), diminished pain intensity

59 ger operative times (393 vs 300 minutes) and blood loss (600 vs 400 mL), but significantly lower oper

60 A significantly higher mean 12-h chest tube blood loss (655 +/- 580 ml vs. 503 +/- 378 ml; p = 0.050

61 oadjuvant chemoradiation (28% vs. 52%); mean blood loss (677 vs. 368 mL); anastomotic leak (14% vs. 9

62 utes, BR: 282 minutes; P = .52), but a lower blood loss (A/R: 300 mL, BR: 500 mL; P < .01) and a shor

63 icantly, consistent with the hypothesis that blood loss activates POMC neurons.

64 he possible role of other external injuries, blood loss, acute stress disorder and the potential for

65 ases, major perioperative complications, and blood loss adversely affected survival.

66 Blood loss after a 4-mm tail snip was measured.

67 important cells in the primary prevention of blood loss after injury.

68 Although blood loss after tail tip amputation was similar in HRG-

69 Blood loss after tail transection significantly decrease

70 e variants shortened clotting times, reduced blood loss after tail-clip assay, and reinstalled clot f

71 ding the possible increases in postoperative blood loss after tonsillectomy when non-steroidal anti-i

72 adherent, shear-resistant thrombi to prevent blood loss after vessel injury.

73 omy was associated with lower intraoperative blood loss, although the clinical significance of this f

74 The mean blood loss among current smokers was significantly highe

75 loss of 43.26 +/- 31.5 mL, whereas the mean blood loss among patients that did not use this medicati

76 ic aorta (Zone 1) can limit subdiaphragmatic blood loss and allow for IV fluid resuscitation when int

77 concentrations and subsequent total reported blood loss and bleeding length by weighted linear mixed-

78 thetic management has reduced intraoperative blood loss and blood product transfusions.

79 RaRP is associated with less blood loss and blood transfusion than open radical prost

80 in patient comfort, and decreased mortality, blood loss and complications, including bladder neck con

81 Statistical improvements in estimated blood loss and conversions to open surgery occurred afte

82 gely the result of the cumulative effects of blood loss and decreased RBC production.

83 lay to recognize bleeding may lead to a high blood loss and increases the risk of death.

84 mortality from unsafe abortion today are not blood loss and infection but, rather, apathy and disdain

85 fected by hookworms causing gastrointestinal blood loss and iron deficiency anemia.

86 g acute illness, the frequent concurrence of blood loss and iron deficiency argue strongly for mainte

87 ivariate analysis (MVA), high mean operative blood loss and large tumor size were independent predict

88 ative time and cost, but decreases estimated blood loss and length of stay.

89 During the operation, there was less blood loss and less need for a wound drain in the laparo

90 More blood loss and longer hospital stays occurred in the fus

91 ber of patients with 500 mL or more surgical blood loss and lowest risk-adjusted 30-day surgical mort

92 while maintaining the advantages of reduced blood loss and morbidity, and greater visualization.

93 aroscopic right hepatectomy allowing for low blood loss and morbidity.

94 oietic recovery from hemolytic anemia, acute blood loss and myeloablation.

95 Off-pump CABG is associated with less blood loss and need for transfusion, less postoperative

96 efficacy and perioperative parameters (i.e. blood loss and pain medication requirements) of LNU to t

97 nal lymphadenectomy and measures to minimize blood loss and postoperative morbidity for maximal survi

98 LDP has lower blood loss and reduced length of hospital stay.

99 d to antigen-unscreened units during massive blood loss and returned to antigen-negative units for th

100 s a potential approach to decrease operative blood loss and shorten recovery.

101 ncreaticoduodenectomy (OPD), including lower blood loss and shorter hospital stay.

102 t causes platelet dysfunction, mucocutaneous blood loss and suppression of erythropoiesis.

103 trauma patient is most commonly secondary to blood loss and the accumulation of fluid in injured tiss

104 ope, iron deficiency is more often caused by blood loss and the cause must be sought and dealt with.

105 ntation (OLT) has been associated with major blood loss and the need for blood product transfusions.

106 tions, but may be accompanied by substantial blood loss and the need for perioperative transfusions.

107 to each other and the vessel wall to prevent blood loss and to facilitate wound repair.

108 of Caesarian section to minimize postpartum blood loss and to further delineate the mass with imagin

109 Blood loss and transfusion are frequent among patients u

110 e offers the potential benefits of decreased blood loss and transfusion rates, reduced analgesic requ

111 fficacy of tranexamic acid (TXA) in reducing blood loss and transfusion requirements during liver tra

112 tomy (PD) can be associated with significant blood loss and transfusion requirements, with potential

113 atectomy can be associated with considerable blood loss and transfusion requirements.

114 brinolytic agents were effective in reducing blood loss and transfusion.

115 Blood loss and transfusions are known to significantly i

116 perative hypotension as a means for reducing blood loss and transfusions.

117 ost-operatively would then lead to increased blood loss and transfusions.We examined 105 consecutive

118 al pressure of 35-40 mm Hg for 20 mins (~40% blood loss), and animals were left in shock for 60 mins.

119 nd-assisted or open procedure, and estimated blood loss), and postoperative variables (transfusion re

120 l frame, longer anesthetic duration, greater blood loss, and a lower percentage of colloid in the non

121 patient education level, type of operation, blood loss, and complications.

122 ions, harvested lymph nodes, operative time, blood loss, and hospital stay were compared using weight

123 nction was evident, with </=135-fold reduced blood loss, and improved buccal bleeding times decreased

124 risk factors for transfusion include anemia, blood loss, and inappropriate transfusion decisions.

125 Operative time, blood loss, and length of stay have dropped substantiall

126 ry correlates closely with the presentation, blood loss, and need for cardiopulmonary bypass to facil

127 ate volume, serum prostate-specific antigen, blood loss, and operative time, only gland volume was si

128 The mean operative time, mean blood loss, and rate of conversion to the open procedure

129 nts included rates of reoperation, amount of blood loss, and transfusion of allogeneic blood.

130 n, length of surgery, vasoactive drugs used, blood loss, and transfusion) were collected prospectivel

131 tinal diseases, evidence of gastrointestinal blood loss, and unexplained iron-deficiency anemia), and

132 s is stimulated, for example following acute blood loss, appropriately enhancing cellular iron export

133 Anemia and operative blood loss are common in the elderly, but evidence is la

134 benefits of earlier convalescence, decreased blood loss, as well as decreased pain.

135 e bleeding (a score of >100 on the pictorial blood-loss assessment chart [PBAC, an objective assessme

136 Even with the best possible management, the blood loss associated with placenta accreta can resemble

137 sured blood loss >/= 1,000 ml; mean measured blood loss at 1, 2, and 24 h after delivery; death; requ

138 le in hemostasis, that is, the prevention of blood loss at sites of mechanical vessel injury.

139 Because of covariation, blood loss, blood transfusion, and complications were te

140 nts were effective in significantly reducing blood loss by 226 to 348 mL and the proportion of patien

141 LDP had lower blood loss by 355 mL (P < 0.001) and hospital length of

142 blood platelets in hemostasis is to prevent blood loss by stable thrombus formation.

143 Outcomes were bleeding duration, blood loss, coagulation parameters, and safety.

144 ; 95% CI, 0.19-1.75; P = .02), and estimated blood loss (coefficient, 0.02; 95% CI, 0.01-0.03; P = .0

145 telets also showed a significant increase in blood loss compared with mice injected with wild-type pl

146 Secondary endpoints were blood loss, conversion rate, postoperative recovery, mor

147 escribes the steps required to achieve a low-blood-loss decerebration in the mouse and approaches for

148 ery of operative blood transfusions to treat blood loss depend not only on the patient and surgery ch

149 Although the estimated blood loss differed significantly between groups (237 mL

150 ated were operative and warm ischemia times, blood loss, donor complications, length of hospital stay

151 crystalloid, colloid, blood products, urine, blood loss, duration, and approach.

152 Increased intraoperative blood loss during HCC resection is an independent progno

153 Pringle maneuver is widely used to minimize blood loss during hepatectomy, without an established ti

154 Moreover, 2 reduced blood loss during liver hepatectomy, while 1 and aprotin

155 Inflow occlusion reduces blood loss during liver transection in selected patients

156 c that has been used successfully to prevent blood loss during major surgery.

157 n used as antifibrinolytic agents to prevent blood loss during major surgery/trauma.

158 udy support previous papers and confirm that blood loss during periodontal surgery is minimal.

159 esults support the hypothesis that degree of blood loss during surgery for colon cancer is a factor t

160 udy tested the hypothesis that the amount of blood loss during surgery for colonic cancer influences

161 The perioperative blood loss during surgery for colorectal cancer relates

162 Blood loss during surgery is an important operative comp

163 fibrinolytic drugs are widely used to reduce blood loss during surgery.

164 Median blood loss during the operation was significantly less (

165 dependent effect of intraoperative estimated blood loss (EBL) on oncologic outcome is unclear.

166 Blood loss, expressed as a percentage of total blood vol

167 The type of surgery performed, overall blood loss, extent of lymphadenectomy, rate of resection

168 enefits to robotic surgery include decreased blood loss, fewer perioperative complications, and decre

169 ng meticulous surgical technique, minimizing blood loss, fluid management can be guided by transesoph

170 ime, islet equivalent (IE) counts, estimated blood loss, fluid resuscitation, and blood transfusions.

171 Mean blood loss from percutaneous cryoablation in this model

172 ignificantly increased bleeding duration and blood loss from pretreatment (experiment 1, 12 subjects)

173 ism in mice without significantly increasing blood loss from surgically challenged animals.

174 The average blood loss from the treated femoral artery during the fi

175 evalence of maternal haemorrhage, defined as blood loss greater than or equal to 1) 500 ml or 2) 1000

176 In patients with intraoperative blood loss > or =800 mL, ANH reduced not only the alloge

177 Secondary outcomes included measured blood loss >/= 1,000 ml; mean measured blood loss at 1,

178 ome of interest was PPH, defined as measured blood loss >/= 500 ml within 24 h of delivery.

179 The prevalence of severe PPH (blood loss >/=1000 ml) was highest in Africa at 5.1% and

180 prevalence of postpartum haemorrhage (PPH) (blood loss >/=500 ml) ranged from 7.2% in Oceania to 25.

181 was PPH, using multiple definitions; (PPH-1) blood loss >/=500 mL; (PPH-2) PPH-1 plus women who recei

182 tients with hypovolemic hypotension once the blood loss has been controlled but before other definiti

183 ed robotic-operative field coupled with less blood loss has paralleled greater understanding of the p

184 rates for patients with significant surgical blood loss have lower adjusted 30-day mortality for thes

185 urgical Apgar Score--based on intraoperative blood loss, heart rate, and blood pressure--that effecti

186 ional issues necessary to respond to massive blood loss in an immediate and sustained manner.

187 Blood loss in critically ill patients may be overt, occu

188 ement in clot formation over protection from blood loss in hemophilia.

189 their use has been restricted to preventing blood loss in hemostatic dysregulation because of poor e

190 nditions, while it only marginally increased blood loss in mice.

191 The primary outcome was blood loss in milliliters between intervention (ie, afte

192 The mean (SD) estimated blood loss in patients with or without embolization was

193 The total blood loss in the animal was <0.5% of the body weight, a

194 For the primary outcome, median blood loss in the fibrinogen group was 50 mL (interquart

195 Interventional radiology may reduce blood loss in these cases.

196 te and coagulation factor isolates, decrease blood loss in trauma patients.

197 ve oxygenation: OR, 0.86, 95% CI, 0.80-0.93; blood loss [in milliliters]: OR, 1.17, 95% CI, 1.05-1.30

198 ment chart [PBAC, an objective assessment of blood loss, in which monthly scores range from 0 to >500

199 re relevant to arterial thrombosis, with 15 (blood loss increase of 2-fold relative to the ED80 value

200 ted that region and method of measurement of blood loss influenced prevalence estimates for both PPH

201 notype (-38% and -17% per allele), estimated blood loss (interacting with INR(3)), smoking status (+2

202 s (longer in the RS group), and in estimated blood loss, intraoperative transfusion, length of stay,

203 Blood loss is a common complication of cardiac surgery.

204 Clamping of vessels to prevent blood loss is integral to liver surgery, but the resulti

205 Blood loss is prevented by the multidomain glycoprotein

206 versions, operative and warm ischemia times, blood loss, length of hospital stay, pain score, convale

207 clude operative techniques, operative times, blood loss, length of stay, conversion rates, morbiditie

208 High blood loss, long operative time, and arterial resections

209 in terms of shorter surgery duration, lower blood loss, lower postoperative pain, faster recovery, i

210 Severe blood loss lowers arterial pressure through a central me

211 e analysis of operative factors demonstrated blood loss <500 mL was predictive of up to a 4-fold impr

212 interval (CI) 17.5-133.3, P = 0.01], reduced blood loss (mean difference = -181 mL, 95% CI -355-(-7.7

213 , respectively; P = .02), and more estimated blood loss (mean, 134 vs. 67 mL, respectively; P = .01).

214 5 women exposed to prophylactic oxytocin had blood loss measured after vaginal delivery at five hospi

215 men not exposed to prophylactic oxytocin had blood loss measured after vaginal delivery at four hospi

216 rative parameters (operation time [OP] time, blood loss, method of pancreas transection, additional o

217 Total blood loss, minimum lesion diameter, maximum lesion diam

218 compared to clopidogrel in the rat surgical blood loss model.

219 me to end of resection phase, intraoperative blood loss, number of transfused units of blood, and pos

220 eater when there is substantial (500-999 mL) blood loss (odds ratio: 0.35, 95% CI: 0.22-0.56 for hema

221 ative time was 318 minutes with an estimated blood loss of 125 mL.

222 operative time of 195 and 258 min, estimated blood loss of 184 and 175 ml, and hospital stay of 2.3 a

223 Blood loss of 250 mL or more during surgery, male gender

224 rative time of 417 minutes, median estimated blood loss of 250 mL, a conversion rate of 3.3%, 90-day

225 Additional blood loss of 300 mL or greater after treatment occurred

226 Additional blood loss of 300 mL or greater after treatment occurred

227 active bleeding within 20 min and additional blood loss of 300 mL or more after treatment.

228 g aspirin (acetylsalicylic acid) showed mean blood loss of 43.26 +/- 31.5 mL, whereas the mean blood

229 odds ratio: 1.81 (1.07-3.07), P = 0.022] and blood loss of more than 500 mL [odds ratio: 1.61 (1.01-2

230 unction, extent of resection, intraoperative blood loss, operative time, incidence and grade of compl

231 We use this assay to show that blood loss or EPO administration increases serum ERFE co

232 deficiency is usually attributed to chronic blood loss or inadequate dietary intake.

233 ac surgery if there is substantial operative blood loss or low preoperative hematocrit levels (<24%).

234 Blood loss or transfusion requirements have been reporte

235 eeding, excess bleeding after surgery, fecal blood loss, or anemia.

236 llstone characteristics, local inflammation, blood loss, or length of stay.

237 spleen after EMH induction by myeloablation, blood loss, or pregnancy.

238 gnancy, procedure, surgery length, operative blood loss, or transfusion requirements, but was positiv

239 demonstrated significant reduction in total blood loss over epsilon-aminocaproic acid (-184 mL; 95%

240 n transection model resulted in the greatest blood loss (P < .01), with a mean (SD) TBV loss of 27.9%

241 s, intended MIDP was associated with reduced blood loss (P = .006) and length of stay (P = .04).

242 he 24-hr period after rFVIIa administration, blood loss (p = .140) and transfusion of packed red bloo

243 h nodes (P = 0.032), and less intraoperative blood loss (P = 0.017) than with the multiple-incision a

244 cant improvement was observed with regard to blood loss, pain, prolapse, and problems with defecation

245 re, pancreatic duct diameter, intraoperative blood loss, pathologic findings of disease, and intraope

246 negative impact of obesity on intraoperative blood loss, perioperative mortality, and reoperation rat

247 Other parameters, such as operative time, blood loss, postoperative renal function, and hospital s

248 Interestingly, tail blood loss progressively decreased at doses greater than

249 the two groups experienced similar amount of blood loss, rate of blood transfusions, overall and majo

250 The tail bleeding time and blood loss remained unaltered, indicating normal hemosta

251 Recovery from blood loss requires a greatly enhanced supply of iron to

252 (1) To measure the incidence of bleeding (blood loss requiring transfusion or intracranial hemorrh

253 hormonal therapy in occult gastrointestinal blood loss resulting from angiodysplasia.

254 dently and completely corrected increases in blood loss resulting from ATIII-dependent anticoagulatio

255 s based primarily on animal studies in which blood loss results from a controlled catheter withdrawal

256 versions (right: 14 [13%] and left: 3 [6%]), blood loss (right: 550 mL [IQR, 350-1150 mL] and left: 3

257 s, hospital course (e.g., lowest hematocrit, blood loss), severity of illness (e.g., Sequential Organ

258 Advantages of RARC are minimal blood loss, shorter hospital stay, quicker recovery, and

259 nclude the use of smaller incisions, reduced blood loss, shorter hospital stays, and surgical refinem

260 the implantation of the bone implants, less blood loss, shorter operation time and reduced radiation

261 presence of severe pulmonary injury, massive blood loss, significant fluid shifts, and hypermetabolis

262 All high-titer type 1 MAbs produced blood loss that was significantly greater than control m

263 ce, whereas all non-inhibitory MAbs produced blood loss that was similar to control.

264 one patient, but safety mechanisms prevented blood loss, the needle was replaced, and treatment conti

265 Outcomes included total blood loss, transfusion of packed red blood cells, reexp

266 ve and postoperative outcomes as measured by blood loss, transfusion rate, R0 negative margin rate, p

267 s BN increased operative duration, estimated blood loss, transfusions, intravenous fluid, and hospita

268 for older surgical patients with significant blood loss varied from 10% to 92%.

269 and the operation duration did not relate to blood-loss volume.

270 When operative blood loss was <500 mL, transfusion was not associated w

271 Median blood loss was 100 mL (50-700) and transfusion rate was

272 and blinded evaluation of the perioperative blood loss was 2.2 (range 0.5 to 5.0) versus 1.4 (range

273 was 234 minutes (range, 60-555 minutes) and blood loss was 200 mL (range, 20-2500 mL) with 10% recei

274 Mean measured blood loss was 341.5 ml (standard deviation [SD] 206.2)

275 inutes (IQR, 270-391 minutes) and the median blood loss was 500 mL (IQR, 250-925 mL).

276 ients aged 65 years or older whose estimated blood loss was 500 mL or greater in 122 Veterans Affairs

277 35 minutes (range, 49-295 minutes), the mean blood loss was 85 mL (range, 10-450 mL), and the mean le

278 Median blood loss was 900 ml, and 22 patients (85%) required bl

279 perative time was 190 min and mean estimated blood loss was equal to 55 ml.

280 Intra-operative blood loss was greater in the EL group by 536.5 mL (95%

281 Estimated blood loss was higher and operative times were longer du

282 Operation time was longer and estimated blood loss was higher in the extended resection group th

283 The blood loss was higher in the junior group.

284 The donor operation lasted 5 hr and blood loss was only 100 mL.

285 Blood loss was used as a surrogate outcome measures.

286 after which saline in amounts to 2 times the blood loss, was administered over 30 mins.

287 sulfate sodium (DSS) had significantly less blood loss, weight loss, colon shortening, colon histolo

288 with known infections or recent significant blood loss were excluded.

289 (38% [n = 27] vs 8% [n = 11], P < 0.001) and blood loss were lower after training and more pancreatic

290 ng-vascular complications, and perioperative blood loss were not identified as predictors.

291 Sex, age, and intraoperative blood loss were not significantly associated with surviv

292 st-operative hemoglobin values and estimated blood loss were the most significant risk factors for ab

293 Ranges of operative times and estimated blood losses were 83 to 225 minutes and 0 to 115 mL, res

294 ters, including operative time and estimated blood loss, were reported between groups.

295 has variably shown increased intraoperative blood loss when compared to hilar controlled procedures.

296 d significantly less distal gastrointestinal blood loss with COX-2 inhibitors than with non-selective

297 or bladder wall may result in extracorporeal blood loss with subsequent iron deficiency.

298 punch biopsy models resulted in most of the blood loss within the first 2 minutes, whereas the splee

299 omplications (OR 0.62; P = 0.001), estimated blood loss (WMD -118.9 mL; P < 0.001), and hospital stay

300 , 95% CI = 29-118], but lower intraoperative blood loss (WMD = -385 mL, 95% CI = -616 to -154), less